Welcome to Rejuvenation Science®!

 Questions? Please call us at
1-888-737-3588 TOLL FREE

Satiety - Appetite Control


1. Heilbronn LK, de JL, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006 Apr 5;295 (13):1539-48.

2. Fontana L. Excessive adiposity, calorie restriction, and aging. JAMA. 2006 Apr 5;295(13):1577-8.

3. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004 Aug;4(8):579-91.

4. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec4;288(21):2709-16.

5. Messier C, Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast. 2005;12(4):311-28.

6. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005 Aug 2;112(5):666-73.

7. Causey JL. Korean pine nut fatty acids [pinolenic acid] induce satiety-producing hormone release in overweight human volunteers. Paper presented at: American Chemical Society National Meeting & Exposition; March 26-30, 2006; Atlanta, GA..

8. Manrique C, Lastra G, Whaley-Connell A, Sowers JR. Hypertension and the cardiometabolic syndrome. J Clin Hypertens. 2005 Aug;7(8):471-6.

9. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol. 2005 May;15(3):167-71.

10. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. AmJMed. 2006 May;119(5 Suppl l):53-9.

11. Capeau J. Insulin signaling: mechanisms altered in insulin resistance. Med Sci (Paris). 2005 Dec;21 Spec No:34-9.

12. Home P. Contributions of basal and postprandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin. 2005 Ju1;21(7):989-98.

13. Ardigo D, Valtuena S, Zavaroni I, Baroni MC, Delsignore R. Pulmonary complications in diabetes mellitus: the role of glycemic control. Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):455-8.

14. Lacquemant C, Vasseur F, Lepretre F, Froguel P Adipocytokins, obesity and development of type 2 diabetes. Med Sci (Paris). 2005 Dec;21 Spec No10-8.

15. Trayhurn P Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand. 2005 Aug;184(4):285=93.

16. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc. 2005 May;64(2):163-9.

17. Bhansali A, Dutta P Pathophysiology of prediabetes. J Indian Med Assoc. 2005 Nov;103 (11):594-5.

18. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006 May; 119(5 Suppl l):S10-6.

19. Little TJ, Horowitz M, Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obes Rev. 2005 Nov;6(4):297-306.

20. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. I Clin Endocrinol Metab. 2001 Sep;86(9):4382-9.

21. Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. Horm Metab Res. 2004 Nov-Dec;36(11-12):811-21.

22. Paquot N, Tappy L. Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis. Rev Med Liege. 2005 May;60(5-6):369-73.

23. Christophe J. Is there appetite after GLP-1 and PACAP? Ann NY Acad Sci. 1998 Dec 11;865:323-35.

24. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20.

25. Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am I Physiol Regul Integr Comp Physiol. 2004 Sep;287(3):R562-7.

26. Marx J. Cellular warriors at the battle of the bulge. Science. 2003 Feb 7;299(5608):846-9.

27. Brennan IM, Feltrin KL, Horowitz M, et al. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am I Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1477-85.

28. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. IntJ Obes Relat Metab Disord. 1999 Mar;23(3):304-11.

29. Schick RR, Schusdziarra V Mossner J, et al. Effect of CCK on food intake in man: physiological or pharmacological effect? Z Gastroenterol. 1991 Feb;29(2):53-8.

30. Adam TC, Westerterp-Plantenga MS. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. BrJNutr. 2005 Jun;93(6):845-51.

31. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humans. Gut. 1995 Feb;36(2):176-9.

32. Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006 Mar;49(3):452-8.

33. Sugano M, Ikeda I, Wakamatsu K, Oka T. Influence of Korean pine (Pinus koraiensis)seed oil containing cis-5,cis-9,cis-l2-octadecatrienoic acid on polyunsaturated fatty acid metabolism, eicosanoid production and blood pressure of rats. Br J Nutr. 1994 Nov;72(5):775-83.

34. Lee JW, Lee KW, Lee SW, Kim IH, Rhee C. Selective increase in pinolenic acid (all-cis5,9,12-18:3) in Korean pine nut oil by crystallization and its effect on LDL-receptor activity. Lipids. 2004 Apr;39(4):383-7.

Reprinted with exclusive permission of Life Extension.